Discontinued — last reported Q3 '19
Operating
Change in fair value of contingent consideration
Biogen Change in fair value of contingent consideration increased by 266.1% to $20.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 113.5%, from $9.60M to $20.50M.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ1 2016
Last reportedQ3 2019
How to read this metric
Increases in liability value may signal that acquired businesses are performing better than expected, requiring higher future payouts.
Detailed definition
This represents the change in the fair value of liabilities related to acquisition earn-outs or performance-based paymen...
Peer comparison
Highly relevant for companies with aggressive M&A strategies, common in the insurance brokerage sector.
Metric ID:
contingent_considerationHistorical Data
8 periods
| Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $23.80M | $9.60M | $13.20M | $5.60M | $20.50M |
| QoQ Change | — | — | — | — | -59.7% | +37.5% | -57.6% | +266.1% |
| YoY Change | — | — | — | — | — | — | -76.5% | +113.5% |
Range$0.00 – $23.80M
Avg YoY Growth+18.5%
Median YoY Growth+18.5%
Change in fair value of contingent consideration at Other Companies
Frequently Asked Questions
- What is Biogen's change in fair value of contingent consideration?
- Biogen (BIIB) reported change in fair value of contingent consideration of $20.50M in Q1 2026.
- How has Biogen's change in fair value of contingent consideration changed year-over-year?
- Biogen's change in fair value of contingent consideration increased by 113.5% year-over-year, from $9.60M to $20.50M.
- What does change in fair value of contingent consideration mean?
- Non-cash adjustments to the estimated future cost of acquisition earn-outs.